Form 8-K - Current report:
SEC Accession No. 0001213900-24-102315
Filing Date
2024-11-26
Accepted
2024-11-25 18:21:18
Documents
14
Period of Report
2024-11-20
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0222579-8k_elevai.htm   iXBRL 8-K 37043
2 CERTIFICATE OF AMENDMENT TO BYLAWS DATED NOVEMBER 20, 2024 ea022257901ex3-1_elevai.htm EX-3.1 6229
  Complete submission text file 0001213900-24-102315.txt   222989

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE elab-20241120.xsd EX-101.SCH 3033
4 XBRL LABEL FILE elab-20241120_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE elab-20241120_pre.xml EX-101.PRE 22371
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0222579-8k_elevai_htm.xml XML 3912
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

EIN.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241497637
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)